Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
March 08 2019 - 3:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led
biopharmaceutical company focused on dermatological and
immuno-inflammatory diseases, today announced it will report
financial results for the fourth quarter and full year 2018,
Monday, March 18th, before U.S. financial markets close.
Management will conduct a conference call at 8:00
AM ET to discuss Aclaris’ financial results and provide a general
business update. The conference call will be webcast live over the
Internet and can be accessed by logging on to the “Investors” page
of the Aclaris Therapeutics website, www.aclaristx.com, prior to
the event. A replay of the webcast will be archived on the Aclaris
Therapeutics website for 30 days following the call.
To participate on the live call, please
dial (844) 776-7782 (domestic) or (661) 378-9535 (international),
and reference conference ID 9765869 prior to the
start of the call.
About Aclaris Therapeutics,
Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, and vitiligo. For
additional information, please visit www.aclaristx.com and
follow Aclaris on LinkedIn.
Aclaris ContactMichael Tung, M.D.Senior Vice
President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President,
Corporate Communications484-321-5559media@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024